ZYBio

ZYBio focuses on the research and development of next-generation probiotics and live biotherapeutics. Based on proprietary intellectual property in strain discovery and drug development, the company has conducted extensive innovative research, establishing "Know-How" from strains to drugs. Its innovative live biotherapeutic product, SK08, is about to enter clinical trials. Building on this, ZYBio will continue to strengthen research and development on the relationship between the human microbiome and diseases, including studies on microbial culture collections and pathobionts, target identification, and the isolation and application of novel functional strains. ZYBio is also a leading platform for the transformation of microbiome innovation achievements in China.